Presentation Date / Time Title Lead Author Abstract # (CDT) Location M7824 Poster Discussion Results from a second-line (2L) NSCLC cohort treated with M7824 (MSB0011359C), a bifunctional fusion protein Sun, Jun 03, targeting PD-L1 Luis G. 11:30 a.m. - and TGF-beta Paz-Ares 9017 12:45 p.m. Arie Crown Theater Oral Presentation Safety and activity of M7824, a bifunctional fusion protein targeting PD-L1 and TGF- beta, in patients with HPV Sat, Jun 02, associated Julius 5:12 p.m. - 5:24 cancers Strauss 3007 p.m. Hall B1 Poster Session Selection of the recommended Phase 2 dose (RP2D) for M7824 (MSB0011359C), a bifunctional fusion protein targeting Mon, Jun 04, TGF-beta and Yulia 8:00 a.m. - PD-L1 Vugmeyster 2566 11:30 a.m. Hall A A sequential cohort study of combination immunotherapy with BN-brachyury vaccine, M7824, ALT-803 and epacadostat in metastatic castration-resist ant prostate Mon, Jun 04, cancer (mCRPC) 8:00 a.m. - (QuEST1) Jason Redman TPS3130 11:30 a.m. Hall A
About M7824
M7824 is an investigational bifunctional immunotherapy that is designed to bring together a TGF-beta trap and 'fuse' it with the anti-PD-L1 mechanism. M7824 is designed to simultaneously block the two immunosuppressive pathways - targeting both pathways aims to control tumor growth by potentially restoring and enhancing anti-tumor responses. M7824 is currently in Phase I studies for solid tumors.
All Merck Press Releases are distributed by e-mail at the same time they become available on the Merck Website. Please go to http://www.merckgroup.com/subscribe to register online, change your selection or discontinue this service.
About Merck
Merck is a leading science and technology company in healthcare, life science and performance materials. Almost 53,000 employees work to further develop technologies that improve and enhance life - from biopharmaceutical therapies to treat cancer or multiple sclerosis, cutting-edge systems for scientific research and production, to liquid crystals for smartphones and LCD televisions. In 2017, Merck generated sales of EUR 15.3 billion in 66 countries.
Founded in 1668, Merck is the world's oldest pharmaceutical and chemical company. The founding family remains the majority owner of the publicly listed corporate group. Merck holds the global rights to the Merck name and brand. The only exceptions are the United States and Canada, where the company operates as EMD Serono, MilliporeSigma and EMD Performance Materials. Contact: Brenda Mulligan +978-821-5345
(Logo: http://photos.prnewswire.com/prnh/201512... )
Photo: http://photos.prnewswire.com/prnh/201512...
